LNK 01001
Alternative Names: EQ-121; LNK-01001; LNK-207Latest Information Update: 28 Dec 2024
Price :
$50 *
At a glance
- Originator Lynk Pharmaceuticals
- Developer EQRx; Lynk Pharmaceuticals; Simcere Pharmaceutical Group
- Class Anti-inflammatories; Antirheumatics; Skin disorder therapies
- Mechanism of Action Janus kinase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Atopic dermatitis; Rheumatoid arthritis
- Phase II Ankylosing spondylitis; Psoriasis
Most Recent Events
- 28 Dec 2024 No recent reports of development identified for phase-I development in Rheumatoid-arthritis in Australia (PO, Tablet)
- 28 Jun 2024 No recent reports of development identified for phase-I development in Rheumatoid-arthritis(In volunteers) in Australia (PO, Capsule)
- 28 Jun 2024 No recent reports of development identified for phase-I development in Rheumatoid-arthritis(In volunteers) in China (PO, Capsule)